Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over....
The incidence and prevalence of Crohn's disease (CD) is rising globally. Patients with moderate to severe CD are at high risk for needing surgery and hospitalization and for developing disease-related complications, corticosteroid dependence, and serious infections. Optimal management of outpatients with...
This guideline covers the management of Crohn's disease in children, young people and adults. It
aims to reduce people's symptoms and maintain or improve their quality of life....
Generar recomendaciones informadas en la evidencia para el tratamiento de los pacientes con enfermedad de Crohn. Apoyar al tratamiento oportuno y seguro de los pacientes de enfermedad de Crohn considerando las minimización de secuelas y la hospitalización. Apoyar a los tomadores de decisiones a formula...
Fator de Necrose Tumoral alfa,
Mercaptopurina,
Azatioprina,
Metotrexato,
Doença de Crohn,
Gastroenterologia,
Mercaptopurina/uso terapêutico,
Metotrexato/uso terapêutico,
Indução de Remissão,
Doença de Crohn/tratamento farmacológico,
Fator de Necrose Tumoral alfa/antagonistas & inibidores
